Drug Profile
Research programme: osteoporosis therapeutics - Zealand Pharma
Alternative Names: ZP 2307Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Zealand Pharma
- Class Peptides
- Mechanism of Action Gap junction modulators; Parathyroid hormone receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoporosis in Denmark
- 09 May 2008 Preclinical development is ongoing
- 11 May 2004 Preclinical trials in Osteoporosis in Denmark (unspecified route)